(12) Translation of european patent specification (11) NO/EP 2384339 B1 (19) NO NORWAY (51) Int Cl. C07K 16/18 (2006.01) A61K 39/395 (2006.01) A61P 19/02 (2006.01) A61P 37/06 (2006.01) A61P 37/08 (2006.01) Norwegian Industrial Property Office (21) Translation Published 2015.07.06 (80) Date of The European Patent Office Publication of the Granted Patent 2015.01.28 (86) European Application Nr. 09774914.7 (86) European Filing Date 2009.12.02 (87) The European Application s Publication Date 2011.11.09 (30) Priority 2008.12.02, GB, 0822011 (84) Designated Contracting States: AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR (73) Proprietor Queen Mary and Westfield College, Mile End Road, London E1 4NS, GB- Storbritannia (72) Inventor PERRETTI, Mauro, William Harvey Research InstituteCentre for Biochemical D'ACQUISTO, Fulvio, William Harvey Research InstituteCentre for Biochemical FLOWER, Roderick, John, William Harvey Research InstituteCentre for Biochemical (74) Agent or Attorney Protector Intellectual Property Consultants AS, Oscarsgate 20, 0352 OSLO, Norge (54) Title TREATMENT OF AUTOIMMUNE DISEASE BY MODULATING ANNEXIN-1 (LIPOCORTIN 1) (56) References Cited: WO-A1-2005/027965 D'ACQUISTO FULVIO ET AL: "Impaired T cell activation and increased Th2 lineage commitment in Annexin-1-deficient T cells." November 2007 (2007-11), EUROPEAN JOURNAL OF IMMUNOLOGY NOV 2007 LNKD- PUBMED:17948261, VOL. 37, NR. 11, PAGE(S) 3131-3142, XP002582223 ISSN: 0014-2980 page 3136, right-hand column - page 3139, right-hand column D'ACQUISTO FULVIO ET AL: "Annexin-1 modulates T-cell activation and differentiation." 1 February 2007 (2007-02-01), BLOOD 1 FEB 2007 LNKD- PUBMED:17008549, VOL. 109, NR. 3, PAGE(S) 1095-1102, XP002582224 ISSN: 0006-4971 the whole document HUITINGA I ET AL: "Effect of annexin-1 on experimental autoimmune encephalomyelitis (EAE) in the rat." January 1998 (1998-01), CLINICAL AND EXPERIMENTAL IMMUNOLOGY JAN 1998 LNKD- PUBMED:9472682, VOL. 111, NR. 1, PAGE(S) 198-204, XP002582225 ISSN: 0009-9104 abstract D'ACQUISTO F ET AL: "Glucocorticoid treatment inhibits annexin-1 expression in rheumatoid arthritis CD4+ T cells." May 2008 (2008-05), RHEUMATOLOGY (OXFORD, ENGLAND) MAY
2008 LNKD- PUBMED:18390587, VOL. 47, NR. 5, PAGE(S) 636-639, XP002582226 ISSN: 1462-0332 abstract LIM L H ET AL: "Promoting detachment of neutrophils adherent to murine postcapillary venules to control inflammation: effect of lipocortin 1." PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 24 NOV 1998 LNKD- PUBMED:9826735, vol. 95, no. 24, 24 November 1998 (1998-11-24), pages 14535-14539, XP002582227 ISSN: 0027-8424 HUGGINS ANTHONY ET AL: "Annexin-1-deficient dendritic cells acquire a mature phenotype during differentiation." April 2009 (2009-04), THE FASEB JOURNAL : OFFICIAL PUBLICATION OF THE FEDERATION OF AMERICAN SOCIETIES FOR EXPERIMENTAL BIOLOGY APR 2009 LNKD- PUBMED:19029200, VOL. 23, NR. 4, PAGE(S) 985-996, XP002582228 ISSN: 1530-6860 abstract
Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (http://worldwide.espacenet.com) or via the search engine on our website here: https://search.patentstyret.no/
1 P a t e n t k r a v 5 1. Et anti-annexin-1 (Anx-A1) antistoff eller et fragment derav som binder seg til Anx-A1 for bruk ved behandlingen av en autoimmun lidelse. 2. Anti-Anx-A1 antistoff eller fragment derav i henhold til krav 1, hvorved nevnte anti-anx-a1antostoff er et monoklonalt antistoff eller et fragment derav. 10 3. Anti-Anx-A1 antistoff eller fragment derav i henhold til krav 2, hvorved det monoklonale antistoffet er humanisert. 15 4. Anti-Anx-A1 antistoff eller fragment derav i henhold til hvilke som helst av kravene 1 til 3, hvorved fragmentet er et Fab, F(ab )2 eller Fv fragment eller et enkeltkjede Fv (scfv) molekyl. 20 25 5. Anti-Anx-A1 antistoff eller fragment derav i henhold til hvilke som helst av de foregående krav, hvorved den autoimmune lidelsen er valgt fra rheumatoid artritt (RA), multippel sklerose (MS) og systemisk lupus erythematose (SLE), Addisons lidelse, Graves lidelse, scleroderma, polymyositt, diabetes mellitus, autoimmun uveoretinitt, ulcerativ kolitt, pemfigus vulgaris, inflammatorisk magelidelse, autoimmun thyroiditt og psoriassis. 30 6. Anti-Anx-A1 antistoff eller fragment derav i henhold til krav 5, hvorved den autoimmune lidelsen er valgt fra rheumatoid artritt (RA), multippel sklerose (MS) og systemisk lupus erythematose (SLE).
-2-7. Anvendelse av en anti-anx-a1 antistoff eller fragment derav som binder til Anx- A1 ved fremstilling av et medikament for behandling av en autoimmun lidelse. 5 10 8. Anvendelse i henhold til krav 7, hvor den hvorved den autoimmune lidelsen er valgt fra rheumatoid artritt (RA), multippel sklerose (MS) og systemisk lupus erythematose (SLE), Addisons lidelse, Graves lidelse, scleroderma, polymyositt, diabetes mellitus, autoimmun uveoretinitt, ulcerativ kolitt, pemfigus vulgaris, inflammatorisk magelidelse, autoimmun thyroiditt og psoriassis. 15 9. Anvendelse i henhold til krav 7, hvor den hvorved den autoimmune lidelsen er valgt fra rheumatoid artritt (RA), multippel sklerose (MS) og systemisk lupus erythematose (SLE).